OSE Immunotherapeutics SA disclosed a $713 million deal with Abbvie Inc. for preclinical-stage monoclonal antibody OSE-230, a potentially first-in-class therapy for treating a range of inflammatory diseases, while Idorsia Ltd. found a partner for two phase III-stage assets in Viatris Inc., as dealmaking continues strong in 2024.
Researchers recently conducted a study to identify small molecules slowing metabolism and mimicking states normally induced by hypothermia or hibernation. The final aim was the discovery of drugs to preserve living cells, tissues and organs ex vivo, and potentially in vivo.
Baseimmune Ltd. has closed $11.3 million (£9 million) in series A funding. The company uses proprietary, deep learning artificial intelligence (AI) to predict future pathogen mutations to generate novel vaccines.
Scientists from the University of Bern have reported preclinical data on KiH_E07_79, a designed ankyrin repeat protein (DARPin) consisting of an Fc fusion construct comprising E07, an immunoglobulin E (IgE)-binding protein, and E2_79, an IgE disruptive domain, fused to an IgG Fc domain via a GS-rich linker.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded US$ 2.2 million to Limmatech Biologics AG to advance the development of its novel vaccine candidate to prevent Neisseria gonorrhoeae infections.
Jasper Therapeutics Inc. has presented data at the AAAAI 2024 conference regarding its CD117-targeting antibody briquilimab and its potential use in allergy and CD117-triggered anaphylactic reactions.
Fochon Biosciences Ltd. has identified apoptosis regulator Bcl-2 (D103E mutant) inhibitors reported to be useful for the treatment of autoimmune disease and cancer.
Plexin domain containing 2 (PLXDC2) is expressed on the surface of several cell types, such as macrophages, dendritic or epithelial cells. Its activation reduces oxidative stress and rebalances the immune response and decreases inflammation. Its activation has been seen to improve disease severity in models of rheumatoid arthritis, while its blockade or loss exacerbates the severity of dextran sulfate sodium (DSS)-induced colitis. Researchers hence tested the PLXDC2 agonist PX-04 (Landos Biopharma Inc.) in a DSS-induced murine model of colitis.
Abbvie Inc. and Tentarix Biotherapeutics Inc. have established a multiyear collaboration focused on the discovery and development of conditionally active, multispecific biologic candidates against one target in oncology and another in immunology.